The Relationship of Genetics,Nursing Practice,and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology

Abstract

An antileukemic agent prescribed for pediatric oncology patients during the maintenance phase of therapy for acute lymphoblastic leukemia, 6-mercaptopurine (6-MP), is highly influenced by genetic variations in the thiopurine S-methyltransferase enzyme. As such, 6-MP must be dosed so that patients with 1 or 2 inactive thiopurine S-methyltransferase alleles will not incur an increased risk for myelosuppression or other toxicities. Informatics tools such as clinical decision support systems are useful for the application of this and similar pharmacogenetics information to the realm of nursing and clinical practice for safe and effective patient care. This article will discuss pharmacogenetics and the associated use of 6-MP; present implications for nursing practice; identify informatics tools such as clinical decision support systems, which can greatly enhance the care of patients whose treatment is based on critical genetic information; and examine the relationship of genetics, nursing practice, and informatics for 6-MP dosing in pediatric oncology.

Keywords

pharmacogenetics dosing 6-mercaptopurine nursing practice informatics clinical decision support

Get full access to this article

View all access options for this article.

References

Anderson

J. A.

Willson

(2008). Clinical decision support systems in nursing: Synthesis of the science for evidence-based practice. CIN: Computers, Informatics, Nursing, 26, 151-158. doi:10.1097/01.NCN.0000304783.72811.8e

Bartlett

(2011). Drug therapy gets personal with genetic profiling. American Nurse Today, 6(5), 23-28.

Bell

G. C.

Crews

K. R.

Wilkinson

M. R.

Haidar

C. E.

Hicks

J. K.

Baker

D. K.

. . . Hoffman

J. M.

(2014). Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association, 21, e93-e99. doi:10.1136/amiajnl-2013-001993

Bhatia

Landier

Hageman

Chen

Kim

Sun

. . . Relling

M. V.

(2015). Systematic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A Children’s Oncology Group study. JAMA Oncology, 1, 287-295. doi:10.1001/jamaoncol.2015.0245

Brownstein

Fusaro

V. A.

Savage

Clinton

Mandl

Margulies

. . . Manzi

(2012). Integration of a standardized pharmacogenomics platform for clinical decision support at Boston Children’s Hospital. BMC Proceedings, 6(Suppl. 6), 5. doi:10.1186/1753-6561-6-S6-P5

Crews

K. R.

Hicks

J. K.

Pui

Relling

M. V.

Evans

W. E.

(2012). Pharmacogenomics and individualized medicine: Translating science into practice. Clinical Pharmacology and Therapeutics, 92, 467-475. doi:10.1038/clpt.2012.120

de Beaumais

T. A.

Fakhoury

Medard

Azougagh

Zhang

Yakouben

Jacqz-Aigrain

. (2011). Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. British Journal of Clinical Pharmacology, 71, 575-584. doi:10.1111/j.1365-2125.2010.03867.x

Dunnenberger

H. M.

Crews

K. R.

Hoffman

J. M.

Caudle

K. E.

Broeckel

Howard

S. C.

. . . Relling

M. V.

(2015). Preemptive clinical pharmacogenetics implementation: Current programs in five United States medical centers. Annual Review of Pharmacology and Toxicology, 55, 89-106. doi:10.1146/annurev-pharmtox-010814-124835

Evans

W. E.

Crews

K. R.

Pui

(2013). A healthcare system perspective on implementing genomic medicine: Pediatric acute lymphoblastic leukemia as a paradigm. Clinical Pharmacology and Therapeutics, 94, 224-229. doi:10.1038/clpt.2013.9

10.

Gehan

E. A.

Freireich

E. J.

(2011). The 6-MP versus placebo clinical trial in acute leukemia. Clinical Trials, 8, 288-297. doi:10.1177/1740774511407358

11.

Greco

Mahon

(2012). Issues up close: Genomic health care has arrived, but are nurses competent to deliver it? American Nurse Today, 7(11), 37-38.

12.

Haga

S. B.

Mills

(2015). Nurses’ communication of pharmacogenetic test results as part of discharge care. Pharmacogenomics, 16, 251-265. doi:10.2217/pgs.14.173

13.

Hopkins

M. M.

Ibarreta

Gaisser

Enzing

C. M.

Ryan

Martin

P. A.

. . . Forde

(2006). Putting pharmacogenetics into practice. Nature Biotechnology, 24, 403-410. doi:10.1038/nbt0406-403

14.

Hudson

K. L.

(2011). Genomics, health care, and society. New England Journal of Medicine, 365, 1033-1041. doi:10.1056/NEJMra1010517

15.

Junglen

L. M.

Pestka

E. L.

Clawson

M. L.

Fisher

S. D.

(2008). Incorporating genetics and genomics into nursing practice: A demonstration. Online Journal of Issues in Nursing, 13(3). doi:10.3912/OJIN.Vol13No03PPT02

16.

Kawamoto

Houlihan

C. A.

Balas

E. A.

Lobach

D. F.

(2005). Improving clinical practice using clinical decision support systems: A systematic review of trials to identify features critical to success. British Medical Journal, 330, 765-772. doi:10.1136/bmj.38398.500764.8F

17.

McGonigle

Mastrian

(2012). Bioinformatics, biomedical informatics, and computational biology. In McGonigle

Mastrian

K. G.

(Eds.), Nursing informatics and the foundation of knowledge (2nd ed., pp. 491-501). Burlington, MA: Jones & Bartlett Learning.

18.

Osheroff

J. A.

Teich

J. M.

Middleton

Steen

E. B.

Wright

Detmer

D. E.

(2007). A roadmap for national action on clinical decision support. Journal of the American Medical Informatics Association, 14, 141-145. doi:10.1197/jamia.M2334

19.

Peterson

J. F.

Bowton

Field

J. R.

Beller

Mitchell

Schildcrout

. . . Denny

J. C.

(2013). Electronic health record design and implementation for pharmacogenomics: A local perspective. Genetics in Medicine, 15, 833-841. doi:10.1038/gim.2013.109

20.

Prows

C. A.

(2011). Infusion of pharmacogenetics into cancer care. Seminars in Oncology Nursing, 27(1), 45-53. doi:10.1016/j.soncn.2010.11.006

21.

Pulley

J. M.

Denny

J. C.

Peterson

J. F.

Bernard

G. R.

Vnencak-Jones

C. L.

Ramirez

A. H.

. . . Roden

D. M.

(2012). Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clinical Pharmacology and Therapeutics, 92(1), 87-95. doi:10.1038/clpt.2011.371

22.

Relling

M. V.

Gardner

E. E.

Sandborn

W. J.

Schmiegelow

Pui

Yee

S. W.

. . . Klein

T. E.

(2011). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology & Therapeutics, 89, 387-391. doi:10.1038/clpt.2010.320

23.

Relling

M. V.

Klein

T. E.

(2011). CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clinical Pharmacology & Therapeutics, 89, 464-467. doi:10.1038/clpt.2010.279

24.

Schmiegelow

Nielsen

S. N.

Frandsen

T. L.

Nersting

(2014). Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: Clinical facts and fiction. Journal of Pediatric Hematology/Oncology, 36, 503-517. doi:10.1097/MPH.0000000000000206

25.

Welch

B. M.

Kawamoto

(2013). Clinical decision support for genetically guided personalized medicine: A systematic review. Journal of the American Medical Informatics Association, 20, 388-400. doi:10.1136/amiajnl-2012-000892